DS
CRVS icon

DRW Securities’s Corvus Pharmaceuticals CRVS Stock Holding History

DRW Securities’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$155K Sell
10,584
-12,800
-55% -$204K ﹤0.01% 1147
2025
Q4 		$180K Buy
+23,384
New +$184K ﹤0.01% 993

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DRW Securities's CRVS Position: Q1 2026 in Review

DRW Securities reduced its Corvus Pharmaceuticals (CRVS) stake by 55% in Q1 2026, selling an estimated $204K and leaving 10,584 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #1147.

DRW Securities first reported a position in CRVS in Q4 2025 and has held it in 2 quarters since. The position peaked at $180K in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • DRW Securities held 10,584 shares of Corvus Pharmaceuticals worth $155K as of Q1 2026.
  • DRW Securities sold 12,800 Corvus Pharmaceuticals shares in Q1 2026, an estimated $204K.
  • Corvus Pharmaceuticals made up ﹤0.01% of DRW Securities's portfolio in Q1 2026, its #1147 holding.
  • DRW Securities first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • DRW Securities's Corvus Pharmaceuticals position peaked at $180K in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.